The European Centre for Disease Prevention and Control (ECDC) has issued an alert about the rapid spread of the drug-resistant fungus Candida auris across hospitals in Europe, with over 4,000 cases reported from 2013 to 2023.

Early detection and swift, coordinated infection control measures are essential to prevent further transmission, but many countries face gaps in surveillance, preparedness, and response systems.

Most cases have been reported in Spain, Greece, Italy, Romania, and Germany, with recent outbreaks in Cyprus and France, and some nations unable to distinguish specific outbreaks due to widespread regional or national transmission.

Candida auris primarily spreads within healthcare settings, and its rapid transition from isolated cases to regional and national outbreaks highlights how quickly it can establish itself in hospitals.

The fungus's swift spread underscores the importance of early detection and coordinated infection control measures to contain outbreaks.

Experts, including Oliver Kurzai from Würzburg, reassured that the risk of infection for individual patients in Germany remains low, as Candida auris is considered a rare occurrence there.

While complete prevention of the fungus's spread is impossible, containment and delay are feasible, and German health authorities emphasize that the current risk remains low.

Most infections are harmless to healthy individuals, but vulnerable groups such as ICU patients and immunocompromised persons are at risk of severe, sometimes fatal, infections like sepsis.

Despite the rising cases, many countries experience sustained local transmission within a few years of initial detection, leaving a narrow window for early intervention to prevent widespread outbreaks.

Funding for new antifungal drugs has been inconsistent, peaking at around US$383 million in 2022, but no new investments have been announced in 2025, hampering research and development efforts.

Laboratory capacity is relatively strong, with 29 countries having access to reference laboratories and 23 providing hospital testing, but the true scale of the problem is likely underreported due to limited systematic surveillance.

The original article on Spiegel's website is no longer accessible, as it is either older than 30 days or has been viewed multiple times, prompting readers to subscribe to SPIEGEL+ for full access.